CLINICAL INVESTIGATOR INDEPENDENCE CERTIFICATION BEING CONSIDERED BY FDA
This article was originally published in The Gray Sheet
Executive Summary
Sponsor certification of clinical investigator independence is one approach under consideration by FDA to address conflict-of- interest concerns. FDA will float the certification idea in a draft policy to be issued later this year. FDA proposed the idea of certification in a draft response to a May 27 letter on financial disclosure sent to FDA Commissioner David Kessler by House Small Business regulation subcommittee Chairman Ronald Wyden (D-Ore.). The subcommittee held a hearing on conflict-of-interest issues on June 17 (see related item, In Brief). Under the proposed policy, sponsors would have the option of certifying the financial independence of clinical investigators or fully disclosing any financial relationship the clinician has with the company. In his letter to the commissioner, Wyden suggested that "some disclosure of those financial ties, and the conflicts-of-interest, be made to [FDA] at the time trial information is evaluated." He added that "a little sunlight may be the best possible disinfectant in such conflict-of-interest matters." FDA held a series of meetings beginning in late March with consumer representatives, physician associations and regulated industry, including the Health Industry Manufacturers Association, on financial disclosure by clinical investigators. In a background paper prepared for the meetings, FDA states that it "believes that there are potential sources of bias that may directly or indirectly influence the outcomes of research." The agency cites certain checks and balances currently included in the evaluation process, including its bioresearch monitoring program, but notes that "no information is available to the agency with respect to financial holdings of clinical investigators." FDA asked the meeting attendees for advice on a number of points, including whether it should require the submission of information on financial interests, at what point during the review process the financial information should be disclosed and information on the ways in which sponsors compensate investigators.
You may also be interested in...
‘Core Pillars’ Of Safety And Innovation Take Center Stage In FDA Reports
The US FDA has issued a pair of reports focused on device safety and innovation. The reports describe recent steps the agency has taken to improve in the two areas, and what it plans to do next.
Lilly Can Rest Easy As Tirzepatide Scores Phase III Sleep Apnea Win
Topline results from two studies in obstructive sleep apnea among obese adults showed efficacy crossing the 50% threshold that physicians have called clinically meaningful.
China’s Public Payer Wants To Define Innovative Drugs As Those With ‘Novel Benefits’
China’s public payer perceives innovative drugs in a different way from that of the country’s top drug regulator, a former senior healthcare security official with knowledge of the matter reveals. The posture has unnerved pharma companies, which have been hit by sharp price discounts.